NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

腦血管疾病治療市場:2020∼2026年

Cerebrovascular Diseases Treatment Market 2020-2026

出版商 Orion Market Research Pvt Ltd 商品編碼 1008057
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
腦血管疾病治療市場:2020∼2026年 Cerebrovascular Diseases Treatment Market 2020-2026
出版日期: 2021年03月30日內容資訊: 英文
簡介

全球腦血管疾病治療的市場規模,在預測期間內預計以5.9%的年複合成長率擴大。推動腦血管疾病治療市場成長的主要原因,是技術的進步和中風增加。再加上新興國家對醫療保健基礎設施的擴大與支出,有利的醫療償付,也對市場成長有大幅貢獻。

但,人們的意識缺乏,缺乏熟練的神經外科醫生和診斷中心,腦血管治療的高成本,是預測期間市場成長的課題。但,醫療保健基礎設施的高成長率與在這個領域的研究數量增加,預計是推動腦血管疾病治療市場的機會。

本報告提供腦血管疾病治療市場相關調查,市場概要,以及中風的各類型,各治療,各終端用戶,各地區的趨勢,及加入此市場的主要企業的簡介等資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和目前市場趨勢

第3章 競爭情形

  • 主要企業分析
    • 概要
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 主要的策略分析

第4章 市場決策要素

  • 促進因素
  • 阻礙因素
  • 市場機會

第5章 市場區隔

  • 全球腦血管疾病治療市場,中風的各類型
    • 缺血性
    • 出血性
  • 全球腦血管疾病治療市場,各治療
    • 藥物治療
    • 外科手術
  • 全球腦血管疾病治療市場,各終端用戶
    • 醫院
    • 外科診所
    • 研究機關

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他
  • 其他地區

第7章 企業簡介

  • Abbott Laboratories
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co.
  • Daiichi Sankyo Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Johnson & Johnson Services, Inc.
  • Medtronic plc
  • Merck & Co., Inc.
  • Penumbra, Inc.
  • Pfizer Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi SA
  • Siemens Healthineers AG
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • United Therapeutics Corp.
目錄
Product Code: OMR2023350

Cerebrovascular Diseases Treatment Market By Type of Stroke (Ischemic and Hemorrhagic), By Treatment (Medical and Surgical Procedure), By End User (Hospitals, Surgical Clinics, and Research Institutes) - Global Industry Share, Growth, Competitive Analysis, And Forecast, 2021-2027

The global cerebrovascular disease treatment market is expected to grow at a considerable CAGR of 5.9% during the forecast period. The major factors that are augmenting the growth of the cerebrovascular disease treatment market are advancement in technology and increasing prevalence of strokes. Furthermore, expansion and spending on healthcare infrastructure in the emerging economies, favorable medical reimbursements are also estimated to be the major factors that are contributing significantly towards the growth of the market. Above 85.0% of the strokes are of ischemic stroke which makes it most commonly caused due to less blood supply to the brain. In addition to this, several government organizations play an important role in the growth of the market. For instance, in 2016, the Society of Vascular and Interventional Neurology (SVIN) started a health campaign of Mission Thrombectomy 2020 to accelerate the access of stroke treatment globally by doubling the normal rate of treatment by 2020. The stroke diseases require early treatment as it is can be life-threatening due to some delay in treatment.

However, the lack of awareness among the people, the absence of skilled neurosurgeons and diagnostic centers, and the high cost of cerebrovascular treatment are some of the restraints that can challenge the growth of the market in the forecast period. Conversely, the high growth rate in healthcare infrastructure and the increasing number of research in the field are the opportunities that are expected to fuel the cerebrovascular diseases treatment market.

Segmental Outlook

The market is segmented on the basis of type of stroke, treatment, and end-user. By type of stroke, the market is segmented into ischemic and Hemorrhagic. The ischemic stroke treatment segment holds a significant market share during the forecast period. Ischemic stroke is driven by the high patient pool, growth in prevalence of stroke, and rise in R&D facilities. The ischemic stroke treatment major players include Bayer AG, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, and Medtronic. Moreover, based on the treatment segment, the market is segmented into medication and surgical procedures. Further, based on the end-user segment, the market is segmented into hospitals, surgical clinics, and research institutes.

Global Cerebrovascular disease treatment Market Share by type of stroke, 2020 (%)

Source: OMR Global

Regional Outlooks

The global cerebrovascular disease treatment market is analyzed based on the geographical regions into North America, Europe, Asia Pacific, and the Rest of the World. North America is estimated to be one of the leading regions in the global cerebrovascular disease treatment market. Increase in R&D investments by the manufacturers, the rising level of hypertension and migraine, advancement and availability of technologies, and government initiatives are the major factor driving the growth of the market in this region. The US is estimated to have the highest share of the market in this region due to the high penetration of patented drugs in the country.

Global Cerebrovascular disease treatment Market Growth, by Region 2021-2027

Source: OMR Global

Asia Pacific is estimated to among the fastest-growing region during the forecast period. The factors promoting the growth of the market in the region include increasing awareness related to heart diseases, increasing disposable income, and increasing incidences related to heart disease due to unhealthy lifestyles. Moreover, favorable government policies to expand healthcare infrastructure in the region such as in China, India, and ASEAN and growth in medical tourism is also driving the market growth.

Market Players Outlook

Key players of the cerebrovascular disease treatment market are Abbott Laboratories, Pfizer Inc., Bristol-Myers Squibb Co., Bayer AG, Amgen Inc., Penumbra, Inc., and Johnson & Johnson Services, Inc. In order to survive in the market, these players adopt different marketing strategies such as mergers, acquisitions, product launches, and geographical expansion so on. For Instance, in October 2020, Bayer AG acquired Asklepios BioPharmaceutical to broaden its platform and potential for the treatment of neuromuscular, central nervous system, cardiovascular and metabolic diseases.

The Report Covers

Market value data analysis of 2019 and forecast to 2026.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global cerebrovascular disease treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Cerebrovascular Disease Treatment Market, By Type of Stroke
    • 5.1.1. Ischemic
    • 5.1.2. Haemorrhagic
  • 5.2. Global Cerebrovascular Disease Treatment Market, By Treatment
    • 5.2.1. Medication
    • 5.2.2. Surgical Procedure
  • 5.3. Global Cerebrovascular Disease Treatment Market, By End User
    • 5.3.1. Hospitals
    • 5.3.2. Surgical Clinics
    • 5.3.3. Research Institutions

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. Amgen Inc.
  • 7.3. AstraZeneca plc
  • 7.4. Bayer AG
  • 7.5. Boehringer Ingelheim International GmbH
  • 7.6. Bristol-Myers Squibb Co.
  • 7.7. Daiichi Sankyo Co. Ltd.
  • 7.8. F. Hoffmann-La Roche Ltd.
  • 7.9. Genentech, Inc.
  • 7.10. Johnson & Johnson Services, Inc.
  • 7.11. Medtronic plc
  • 7.12. Merck & Co., Inc.
  • 7.13. Penumbra, Inc.
  • 7.14. Pfizer Inc.
  • 7.15. Sangamo Therapeutics, Inc.
  • 7.16. Sanofi SA
  • 7.17. Siemens Healthineers AG
  • 7.18. Sihuan Pharmaceutical Holdings Group Ltd.
  • 7.19. Takeda Pharmaceutical Co. Ltd.
  • 7.20. United Therapeutics Corp.

LIST OF TABLES

  • 1. GLOBAL CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE OF STROKE, 2020-2027($ MILLION)
  • 2. GLOBAL ISCHEMIC MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLION)
  • 3. GLOBAL HEMORRHAGIC MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLION)
  • 4. GLOBAL CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 5. GLOBAL MEDICATION MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLION)
  • 6. GLOBAL SURGICAL PROCEDURE MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLION)
  • 7. GLOBAL CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY END USER, 2020-2027($ MILLION)
  • 8. GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLION)
  • 9. GLOBAL SURGICAL CLINICS MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLION)
  • 10. GLOBAL RESEARCH INSTITUTIONS MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLION)
  • 11. NORTH AMERICAN CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 12. NORTH AMERICAN CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE OF STROKE, 2020-2027($ MILLION)
  • 13. NORTH AMERICAN CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 14. NORTH AMERICAN CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY END USER, 2020-2027($ MILLION)
  • 15. EUROPEAN CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 16. EUROPEAN CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE OF STROKE, 2020-2027($ MILLION)
  • 17. EUROPEAN CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 18. EUROPEAN CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY END USER, 2020-2027($ MILLION)
  • 19. ASIA PACIFIC CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
  • 20. ASIA PACIFIC CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS, BY TYPE OF STROKE, 2020-2027($ MILLION)
  • 21. ASIA PACIFIC CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)

22. ASIA PACIFIC CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY END USER, 2020-2027($ MILLION

  • 23. REST OF WORLD CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TYPE OF STROKE, 2020-2027($ MILLION)
  • 24. REST OF THE WORLD CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
  • 25. REST OF THE WORLD CEREBROVASCULAR DISEASE TREATMENT MARKET RESEARCH AND ANALYSIS BY END USER, 2020-2027($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CEREBROVASCULAR DISEASE TREATMENT MARKET SHARE BY TYPE OF STROKE, 2020 VS 2027 (%)
  • 2. GLOBAL CEREBROVASCULAR DISEASE TREATMENT MARKET SHARE BY TREATMENT, 2020 VS 2027 (%)
  • 3. GLOBAL CEREBROVASCULAR DISEASE TREATMENT MARKET SHARE BY END USER, 2020 VS 2027 (%)
  • 4. GLOBAL CEREBROVASCULAR DISEASE TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 5. GLOBAL ISCHEMICTREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 6. GLOBAL HAEMORRHAGICTREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 7. GLOBAL CEREBROVASCULAR DISEASE TREATMENT THROUGH MEDICATIONMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 8. GLOBAL CEREBROVASCULAR DISEASE TREATMENT THROUGH SURGICAL PROCEDURES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL HOSPITALSCEREBROVASCULAR DISEASE TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 10. GLOBAL SURGICAL CLINICSCEREBROVASCULAR DISEASE TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 11. GLOBAL RESEARCH INSTITUTIONSCEREBROVASCULAR DISEASE TREATMENT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 12. US CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 13. CANADA CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 14. 2020-2027UK CEREBROVASCULAR DISEASE TREATMENT SIZE 2020-2027($ MILLION)
  • 15. GERMANY CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 16. SPAIN CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 17. FRANCE CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 18. ITALY CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 19. REST OF EUROPECEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 20. 2020-2027CHINA CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 21. INDIA CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 22. JAPAN CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 23. REST OF ASIA PACIFICCEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)
  • 24. REST OF WORLD CEREBROVASCULAR DISEASE TREATMENT MARKET SIZE, 2020-2027($ MILLION)